Hla matched cord blood CP and ASD children’s clinical trails in Russia

Hère 2 clinical trails ( they are taking international patients but on payment basis you can ask)

Hère links on official trails on clinical trails.gov:

( with allogenic cord blood)

Cp

https://clinicaltrials.gov/ct2/show/NCT04098029

And ASD:

https://clinicaltrials.gov/ct2/show/NCT04099381

Hère new instructions for mails:

( at the stage you get person number you need to send NEW mail with number given) ! I did mistake to answer previous mail don’t repeat my mistakes 😉

So here instruction ver explicit : ( read well all points)

NSTRUCTIONS FOR TRANSFER OF INFORMATION BY EMAIL FOR CLINICAL TESTS

Email ct@cordbank.ru is designed for patients participating or planning to participate in clinical trials at the Dynasty Medical Center.

Sending messages to this e-mail indicates that you agree to the transmission of data, medical and other personal information via an open (unprotected by special means) communication channel.

Email is set up to help the researcher sort the letters and respond to them in a timely manner. When contacting the email address ct@cordbank.ru must follow the next rules, in case of the rules are not met, the researcher does not guarantee a response to the letter.

Incoming emails are processed in English and Russian, dates are displayed in DD / MM / YYYY format:

1. PRIMARY REQUEST FOR CLINICAL TESTS.

For the initial request for clinical trials, a letter should be sent to the researcher with the following heading:

PRIMARY _ CT _ REQUEST _ XX ,

Where XX indicate the clinical trial option: CP for cerebral palsy, AU – for autism;

Inside the letter you must provide the following information on the form:

Additionally, we request (this will help us to quickly determine the possibility of treatment) the most complete information about: is current medical condition of the patient, a brief description any held treatment and its effectiveness.

Further correspondence is conducted by replying to the previous letter so that the history of the correspondence is not interrupted. Please do not manually change the message header, do not send repeated requests and do not send new emails with attachments. If you are included in the study, you will be given a number with which you will continue to correspond with the researcher (see point 2).

2. FOR PATIENTS AT THE FIRST STAGE OF CLINICAL STUDY (SELECTION)

Patients included in the first stage of the study (selection) receive from the researcher an individual number that will need to be reflected in the title. Please make a NEW email with a NEW header. The new header will automatically sort your letters in the working group. Please write the first letter after entering the first stage of a clinical trial according to the following pattern:

CT_XX_S1 NNN,

Where XX – clinical trial option: CP for cerebral palsy, AU – for autism; NNN – a unique individual

number assigned to you by the researcher.

Patients can ask questions; send the requested documents (pdf, jpeg) at any time. Further correspondence is conducted by replying to the previous letter so that the history of the correspondence is not interrupted. Please do not manually change the message header, do not send repeated requests and do not send new emails with attachments.

Name of the patient

Date of Birth

Diagnosis

dates of diagnosis

Patient weight

Level GMFCS or ATEC

3. FOR PATIENTS ON THE SECOND AND THE THIRD STAGE OF A CLINICAL RESEARCH (SELECTION OF A GROUP AND PROCEDURE FOR THE INTRODUCTION OF CELLS).

After you have been assigned to the first or second study groups, and later, throughout the duration of the procedures, you can communicate with the researcher at any time on the topic of the clinical study. In order for you to receive prompt responses, you should change the subject of the heading in the following pattern:

CT _ XX _ S 2-3 NNN,

Where XX – clinical trial option: CP for cerebral palsy, AU – for autism; NNN – a unique individual

number assigned to you by the researcher in the second stage.

4. AFTER CONDUCTING THE INTRODUCTION OF CELLS.

After the first infusion of cells, the second infusion and until the end of the study, patients should transmit information about the effectiveness of treatment, for this, it is necessary to arrange the letter header as follows:

CT _ XX _ S 4 NNN,

Where XX – clinical trial option: CP for cerebral palsy, AU – for autism; NNN – a unique individual

number assigned to you by the researcher in the second stage.

All subsequent letters with research results should be sent in response to the first letter, without changing the title. Any questions or events about undesirable reactions should be sent to the researcher with such a title.

Инструкция по передачи информации по электронной почте для клинических испытаний. V003.02072019

Laisser un commentaire